Gilead Sciences, Inc.
INHIBITORS OF PEPTIDYLARGININE DEIMINASES

Last updated:

Abstract:

The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Status:
Application
Type:

Utility

Filling date:

21 Dec 2021

Issue date:

21 Jul 2022